BIOMAT Database Logo BIOMAT Database Logo

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. 2001

M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza 35, 20122 Milan, Italy. maurimc@polic.cilea.it

Twenty-four chronic schizophrenic outpatients with a mean age of 37.21 years +/- 9.96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4.46 mg/die +/- 1.30 SD, mean 0.06 mg/kg +/- 0.01 SD) for a year. Clinical evaluation was assessed with the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Symptoms Scale (PANSS), Extrapyramidal Side Effects Rating Scale (EPSE) and a checklist for Anticholinergic Side Effects (ACS) at T0, then after 1 (T1), 2 (T2), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months. RSP and 9-hydroxy-risperidone (9OH-RSP) plasma levels were determined at T12 by the HPLC method. BPRS and PANSS mean values showed a significant improvement during the study. No correlation between RSP dosage (mg/kg) and RSP, 9OH-RSP plasma levels or active moiety resulted. A positive correlation between age and active moiety was observed. A positive correlation between RSP and 9OH-RSP plasma levels was observed. A curvilinear relationship between active moiety and PANSS improvement (%) was observed. Patients with the higher PANSS amelioration showed RSP + 9OH-RSP plasma levels ranging from 15 to 30 ng/mL. RSP seems to be quite an effective drug. It seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010054 Brief Psychiatric Rating Scale A scale comprising 18 symptom constructs chosen to represent relatively independent dimensions of manifest psychopathology. The initial intended use was to provide more efficient assessment of treatment response in clinical psychopharmacology research; however, the scale was readily adapted to other uses. (From Hersen, M. and Bellack, A.S., Dictionary of Behavioral Assessment Techniques, p. 87) Overall and Gorham Brief Psychiatric Rating Scale,Overall-Gorham Brief Psychiatric Rating Scale,Overall Gorham Brief Psychiatric Rating Scale
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone.
June 2004, Journal of clinical psychopharmacology,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.
May 1998, International clinical psychopharmacology,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response.
January 2006, Journal of psychiatric practice,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
August 2006, Human psychopharmacology,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
August 2012, The Journal of clinical psychiatry,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Long-term treatment with mianserin: a clinical study with plasma levels.
January 1982, Advances in biochemical psychopharmacology,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
[Long-term treatment of chronic schizophrenia].
September 1998, Der Nervenarzt,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Risperidone-induced long-term weight gain in a patient with schizophrenia.
March 2004, The Australian and New Zealand journal of psychiatry,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.
January 1995, Clinical therapeutics,
M C Mauri, and V Laini, and L Boscati, and R Rudelli, and V Salvi, and R Orlandi, and P Papa
[PSYCHOPHARMACOLOGICAL LONG-TERM TREATMENT OF CHRONIC SCHIZOPHRENIA].
December 1963, Die Medizinische Welt,
Copied contents to your clipboard!